Drugs / D930
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05207761 | Jan → Oct 2022 | glaucoma | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT03034486 | Feb → Mar 2017 | — | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03762369 | Dec 2018 → Feb 2022 | ocular hypertension, open-angle glaucoma | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | D930 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03762369 ↗ |